Every reference with a DOI in the deposited reference list resolved to a known
work in Crossref or DataCite at the dated check, and none carried a retraction,
withdrawal, or removal notice.
The 39 checked references that resolve
resolves10.1038/nrrheum.2016.61Toll-like receptors and chronic inflammation in rheumatic diseases: new developments
resolves10.1155/2018/9874109The Role of Toll-Like Receptor Signaling in the Progression of Heart Failure
resolves10.1371/journal.pone.0057348In Vivo Knockdown of TAK1 Accelerates Bone Marrow Proliferation/Differentiation and Induces Systemic Inflammation
resolves10.1002/ptr.3513Effect of<i>Salvia miltiorrhiza</i>Hydrophilic Extract on Antioxidant Enzymes in Diabetic Patients with Chronic Heart Disease: A Randomized Controlled Trial
resolves10.1002/ptr.4611Effect of <i>Salvia miltiorrhiza</i> Hydrophilic Extract on the Endothelial Biomarkers in Diabetic Patients with Chronic Artery Disease
resolves10.1038/srep36949Qishen granules inhibit myocardial inflammation injury through regulating arachidonic acid metabolism
resolves10.1016/j.hlc.2019.11.013Prognostic Value of Lactate Dehydrogenase for Mid-Term Mortality in Acute Decompensated Heart Failure: A Comparison to Established Biomarkers and Brain Natriuretic Peptide
resolves10.1142/S0192415X15500020Compound Danshen (<i>Salvia miltiorrhiza</i>) Dripping Pill for Coronary Heart Disease: An Overview of Systematic Reviews
resolves10.1016/j.acvd.2016.10.004COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response
resolves10.1016/j.pharmthera.2018.01.001Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities
resolves10.1097/CCM.0b013e3181b77fe3Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis*
resolves10.1001/jama.2013.2194Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
resolves10.1016/j.phymed.2018.04.027Evaluations of the effect of HuangQi against heart failure based on comprehensive echocardiography index and metabonomics
resolves10.1155/2013/149363Effect of<i>Crataegus</i>Usage in Cardiovascular Disease Prevention: An Evidence-Based Approach
resolves10.1155/2011/378907Neuron Regeneration and Proliferation Effects of Danshen and Tanshinone IIA
resolves10.1016/j.jacc.2013.11.023In Vivo Silencing of the Transcription Factor IRF5 Reprograms the Macrophage Phenotype and Improves Infarct Healing
resolves10.1161/CIRCULATIONAHA.118.035047IL (Interleukin)-10–STAT3–Galectin-3 Axis Is Essential for Osteopontin-Producing Reparative Macrophage Polarization After Myocardial Infarction
resolves10.1093/cvr/cvt047Extracellular HSP60 induces inflammation through activating and up-regulating TLRs in cardiomyocytes
resolves10.1161/CIRCRESAHA.113.301198Enhanced Efferocytosis of Apoptotic Cardiomyocytes Through Myeloid-Epithelial-Reproductive Tyrosine Kinase Links Acute Inflammation Resolution to Cardiac Repair After Infarction
resolves10.1016/j.jacc.2016.05.0112016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
checked 2026-07-23 — re-checked daily as this page is visited;
titles and statuses come from Crossref and DataCite and are not part of the signed record
Both snippets point at the live badge image and link back to this page. The
badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.